Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA

Principal Financial Group Inc. cut its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 14.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,323,041 shares of the biotechnology company’s stock after selling 223,394 shares during the period. Principal Financial Group Inc. owned 0.55% of ADMA Biologics worth $19,396,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. State Street Corp grew its position in ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock valued at $219,950,000 after acquiring an additional 637,727 shares during the period. Geode Capital Management LLC lifted its stake in shares of ADMA Biologics by 4.3% in the 2nd quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock valued at $107,691,000 after purchasing an additional 245,309 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of ADMA Biologics by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after purchasing an additional 358,627 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of ADMA Biologics by 24.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock worth $60,719,000 after purchasing an additional 826,415 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in ADMA Biologics by 8.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock worth $59,366,000 after purchasing an additional 271,305 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Price Performance

ADMA stock opened at $16.43 on Monday. The firm has a market cap of $3.91 billion, a P/E ratio of 19.10 and a beta of 0.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The stock has a 50-day simple moving average of $18.35 and a 200-day simple moving average of $17.02.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.